The following clinical trials are currently offered in Germany in this group. More about Lymphoblastic Neoplasms
34 matching trials
The GMALL Registry Study is an observational study of adult patients with a specific type of blood cancer (acute lymphoblastic leukemia, ALL).
18–55 years · Relapsed / refractory · Phase IV
Lymphoblastic lymphoma (LBL) is a malignant disease of the lymphatic system that primarily affects children and adolescents. The brain (CNS) can also be affected by LBL. The LBL2018 study is investigating whether a change to the current standard treatment protocol can reduce the risk of relapse involving the CNS. Children and adolescents under the age of 18 with newly diagnosed lymphoblastic lymphoma are eligible to participate in the study; no new drugs are being tested.
0–18 years · First line · Phase III
Acute lymphoblastic leukemia (ALL) in children and adolescents is now very treatable thanks to intensive therapies. However, the medications used also carry a risk of side effects (toxicity). It is now also possible to accurately assess the severity and prognosis of ALL. The goal of the AIEOP-BFM ALL 2017 study is to make treatment more targeted and better tolerated—including through the use of immunotherapy with blinatumomab instead of highly toxic chemotherapy in high-risk patients. In addition, other targeted medications such as bortezomib and extended chemotherapy phases are used in certain subgroups to better prevent relapses. Patients up to 17 years of age with previously untreated ALL and certain subtypes are eligible to participate in this study.
0–17 years · First line · Phase III
Many types of cancer can now be cured using modern treatment options. Nevertheless, relapses and progressive cancer remain a major challenge. The goal of the INFORM-REGISTER study is to use molecular genetic testing methods to gather information about tumor characteristics that can be used by treating physicians to inform future treatment decisions. Patients aged 0 to 40 with previously treated, treatment-resistant, or progressive cancer who no longer have any established curative treatment options available are eligible to participate in the study.
0–40 years · Relapsed / refractory · Phase IV
Acute lymphoblastic leukemia (ALL) is a type of blood cancer that progresses rapidly and requires intensive treatment. Significant progress has been made in treatment in recent years; however, these intensive treatment regimens are often not suitable for older patients. The INITIAL-1 study is investigating the efficacy and safety of inotuzumab ozogamicin without additional intensive chemotherapy in older ALL patients. Eligible participants include women and men who have a new diagnosis of ALL (>25% blasts) and who are not eligible for the standard intensive therapy due to their age (>75 years) or pre-existing conditions (starting at age 56).
56 years and older · First line · Phase II
Acute lymphoblastic leukemia (ALL) is a malignant disease of the lymphatic system that is typically treated according to a fixed treatment protocol, often the GMALL protocol (German Multicenter Study Group for Adult ALL). The GMALL registry study collects data on the diagnosis, treatment, and outcomes of patients, as well as biological samples. No new drugs or therapies are being tested in this study. Women and men aged 18 and older with ALL or related forms of ALL who are being treated according to a GMALL treatment protocol are eligible to participate in the study.
18 years and older
The standard treatment for relapsed acute lymphoblastic leukemia (ALL) in children and adolescents is intensive chemotherapy, usually followed by a stem cell transplant. Combining standard therapy with the drug bortezomib could potentially improve treatment outcomes. The goal of the IntReALL HR 2010 study is to investigate standard chemotherapy in combination with bortezomib. Bortezomib is already used to treat other blood cancers, but the drug has not yet been approved for the treatment of relapsed ALL in children and adolescents. Children and adolescents under the age of 18 with a first relapse of ALL may participate, provided they have their parents’ consent. They must not have previously received a stem cell transplant for the treatment of this blood cancer and must test negative for the BCR-ABL genetic mutation.
up to 17 years · First line · Phase II
B-cell precursor acute lymphoblastic leukemia (B-precursor ALL) is a malignant disease of the hematopoietic system that requires intensive treatment. Older people or those with pre-existing conditions often tolerate this therapy less well, making an effective but less intensive treatment option desirable. The aim of this study is to investigate the efficacy and safety of blinatumomab in combination with lower-dose chemotherapy compared to standard therapy. Patients aged 55 or older, or 40 or older with pre-existing conditions, who have B-precursor ALL are eligible to participate in the study.
40 years and older · First line · Phase III
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a malignant cancer of the hematopoietic system that most commonly occurs in childhood. Despite good results with established standard therapies, the disease may become active again (relapse). For adults, the drug inotuzumab ozogamicin (InO) is already approved for the treatment of ALL. The goal of this study is to investigate the efficacy of treatment with inotuzumab ozogamicin (InO) in patients experiencing their first relapse, compared to standard therapy. Women and men between the ages of 1 and 17 with their first high-risk relapse of BCP-ALL are eligible to participate in this study.
1–17 years · Relapsed / refractory · Phase II
Acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (NHL) are malignant diseases of the blood and lymphatic system. CAR-T cells represent a new treatment option and are already approved for use in certain situations. This study investigates the safety, efficacy, and optimal dosage of MB-CART19.1, a new, as-yet-unapproved CAR-T cell therapy. Patients with CLL, ALL, or NHL can participate in this study starting at age 2.
1 years and older · Relapsed / refractory · Phase I/II
